X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 13.9 17.8 78.2% View Chart
P/BV x 3.0 1.1 267.3% View Chart
Dividend Yield % 0.4 1.6 26.4%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-19
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8093,303 24.5%   
Low Rs5041,797 28.0%   
Sales per share (Unadj.) Rs281.1716.5 39.2%  
Earnings per share (Unadj.) Rs41.479.7 51.9%  
Cash flow per share (Unadj.) Rs50.9107.9 47.2%  
Dividends per share (Unadj.) Rs2.5028.00 8.9%  
Dividend yield (eoy) %0.41.1 34.7%  
Book value per share (Unadj.) Rs199.41,477.5 13.5%  
Shares outstanding (eoy) m585.88184.45 317.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.33.6 65.6%   
Avg P/E ratio x15.932.0 49.6%  
P/CF ratio (eoy) x12.923.6 54.6%  
Price / Book Value ratio x3.31.7 190.8%  
Dividend payout %6.035.1 17.2%   
Avg Mkt Cap Rs m384,630470,292 81.8%   
No. of employees `00017.37.8 221.6%   
Total wages/salary Rs m21,30822,504 94.7%   
Avg. sales/employee Rs Th9,500.716,899.4 56.2%   
Avg. wages/employee Rs Th1,229.42,877.7 42.7%   
Avg. net profit/employee Rs Th1,397.91,879.9 74.4%   
INCOME DATA
Net Sales Rs m164,666132,153 124.6%  
Other income Rs m1,0203,128 32.6%   
Total revenues Rs m165,686135,281 122.5%   
Gross profit Rs m37,71866,290 56.9%  
Depreciation Rs m5,5805,202 107.3%   
Interest Rs m77744,097 1.8%   
Profit before tax Rs m32,38020,119 160.9%   
Minority Interest Rs m313,194 1.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1838,611 95.0%   
Profit after tax Rs m24,22914,701 164.8%  
Gross profit margin %22.950.2 45.7%  
Effective tax rate %25.342.8 59.0%   
Net profit margin %14.711.1 132.3%  
BALANCE SHEET DATA
Current assets Rs m121,878122,742 99.3%   
Current liabilities Rs m86,806310,810 27.9%   
Net working cap to sales %21.3-142.3 -15.0%  
Current ratio x1.40.4 355.5%  
Inventory Days Days13023 563.0%  
Debtors Days Days6839 176.0%  
Net fixed assets Rs m81,037116,904 69.3%   
Share capital Rs m586369 158.8%   
"Free" reserves Rs m116,218272,161 42.7%   
Net worth Rs m116,804272,530 42.9%   
Long term debt Rs m4,512270,196 1.7%   
Total assets Rs m211,052856,261 24.6%  
Interest coverage x42.71.5 2,929.7%   
Debt to equity ratio x01.0 3.9%  
Sales to assets ratio x0.80.2 505.5%   
Return on assets %11.86.9 172.5%  
Return on equity %20.75.4 384.5%  
Return on capital %27.412.4 220.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72715,200 531.1%   
Fx outflow Rs m34,7004,889 709.8%   
Net fx Rs m46,02710,312 446.4%   
CASH FLOW
From Operations Rs m19,548-115,975 -16.9%  
From Investments Rs m-19,570-8,265 236.8%  
From Financial Activity Rs m8,642107,525 8.0%  
Net Cashflow Rs m8,922-16,650 -53.6%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Dividend Stocks Amid Volatile Stock Markets; US-China Trade War and More(Podcast)

The market, which has been caught in the grip of the bears, gave a negative yearly return for first time in last eight years.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

7 Stocks to Buy in Today's Difficult Market(The 5 Minute Wrapup)

Aug 5, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

My Top 3 Dividend Millionaire Stocks(Profit Hunter)

Aug 7, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 16, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS